JP2001522241A - 診断方法および試薬 - Google Patents
診断方法および試薬Info
- Publication number
- JP2001522241A JP2001522241A JP54254598A JP54254598A JP2001522241A JP 2001522241 A JP2001522241 A JP 2001522241A JP 54254598 A JP54254598 A JP 54254598A JP 54254598 A JP54254598 A JP 54254598A JP 2001522241 A JP2001522241 A JP 2001522241A
- Authority
- JP
- Japan
- Prior art keywords
- disease
- sequence
- protein
- rna
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Psychology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4316397P | 1997-04-10 | 1997-04-10 | |
US60/043,163 | 1997-04-10 | ||
PCT/IB1998/000705 WO1998045322A2 (fr) | 1997-04-10 | 1998-04-02 | Reactifs pour diagnostics et procede correspondant |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001522241A true JP2001522241A (ja) | 2001-11-13 |
Family
ID=21925819
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54254598A Pending JP2001522241A (ja) | 1997-04-10 | 1998-04-02 | 診断方法および試薬 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0971952A2 (fr) |
JP (1) | JP2001522241A (fr) |
AU (1) | AU7071598A (fr) |
CA (1) | CA2287084A1 (fr) |
WO (1) | WO1998045322A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005026353A1 (fr) * | 2003-09-16 | 2005-03-24 | Sumitomo Chemical Company, Limited | Procede pour evaluer le degre de cancerisation |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO314086B1 (no) * | 1998-05-08 | 2003-01-27 | Gemvax As | Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til |
WO2001040804A2 (fr) * | 1999-12-03 | 2001-06-07 | Koninklijke Nederlandse Akademie Van Wetenschappen | Clairance d'une proteine aberrante associee a une maladie |
WO2003008970A1 (fr) * | 2001-07-19 | 2003-01-30 | Sysmex Corporation | Procede de detection de ps2v |
WO2004001421A2 (fr) * | 2002-06-21 | 2003-12-31 | Innogenetics N.V. | Procede de diagnostic et diagnostic differentiel des maladies neurologiques |
CA2547165C (fr) | 2003-11-25 | 2014-07-08 | Ira H. Pastan | Anticorps anti-cd22 et immunoconjugues mutes |
FR2869909B1 (fr) * | 2004-05-04 | 2007-12-21 | Univ Angers | Peptide capable d'inhiber la polymerisation de la tubuline et son utilisation pour inhiber la proliferation cellulaire |
EP1916259A1 (fr) | 2006-10-26 | 2008-04-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Fragment SCFV anti-gycoprotéine VI pour le traitement de la thrombose |
PT2238170T (pt) | 2008-01-31 | 2017-02-21 | Inserm - Inst Nat De La Santé Et De La Rech Médicale | Anticorpos contra cd39 humano e seu uso para inibição da actividade de células t reguladoras |
US8481033B2 (en) | 2008-10-07 | 2013-07-09 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (PF4V1) |
WO2010106051A1 (fr) | 2009-03-17 | 2010-09-23 | Universite De La Mediterranee | Anticorps anti-btla et leurs utilisations |
US9187568B2 (en) | 2009-05-07 | 2015-11-17 | Stallergenes S.A. | Use of IgG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route |
JP2009203240A (ja) * | 2009-06-15 | 2009-09-10 | National Institute Of Advanced Industrial & Technology | リポソームおよびそれからなる細胞への物質導入担体 |
WO2011032022A1 (fr) | 2009-09-11 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Exotoxine a pseudomonias améliorée à immunogénicité réduite |
WO2011080322A1 (fr) | 2009-12-30 | 2011-07-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Méthode de pronostic de l'issue d'une hémophilie acquise et de traitement de l'hémophilie |
WO2012010696A1 (fr) | 2010-07-23 | 2012-01-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes de gestion du cancer ciblant co-029 |
EP2412724A1 (fr) | 2010-07-29 | 2012-02-01 | Centre National de la Recherche Scientifique (C.N.R.S) | Régulation de l'activité 4 glypican pour moduler le sort de cellules souches et leurs utilisations |
WO2012080769A1 (fr) | 2010-12-15 | 2012-06-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticorps anti-cd277 et leurs utilisations |
WO2012085132A1 (fr) | 2010-12-22 | 2012-06-28 | Orega Biotech | Anticorps contre cd39 humain et utilisation de ceux-ci |
WO2012101125A1 (fr) | 2011-01-24 | 2012-08-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticorps spécifiques dirigés contre le cxcl4 humain et leurs utilisations |
BR112013019975A2 (pt) | 2011-02-28 | 2017-08-01 | Hoffmann La Roche | proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira" |
WO2012131004A2 (fr) | 2011-03-31 | 2012-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticorps dirigés contre icos et utilisation de ceux-ci |
US10683362B2 (en) | 2011-05-06 | 2020-06-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant immunotoxin targeting mesothelin |
US9127065B2 (en) | 2011-05-19 | 2015-09-08 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anti-human HER3 antibodies and uses thereof |
CA2838013C (fr) | 2011-06-09 | 2023-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Exotoxine de pseudomonas ayant moins d'epitopes immunogenes de lymphocytes t et/ou de lymphocytes b |
US9409988B2 (en) | 2011-06-22 | 2016-08-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-Axl antibodies and uses thereof |
US9249228B2 (en) | 2011-06-22 | 2016-02-02 | Oribase Pharma | Anti-Axl antibodies and uses thereof |
US9434766B2 (en) | 2011-06-27 | 2016-09-06 | Universite Pierre Et Marie Curie (Paris 6) | CCR2 antagonist peptides |
EP2543679A1 (fr) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticorps pour la prévention et le traitement de la thrombose |
EP2543677A1 (fr) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticorps pour la prévention et le traitement de la thrombose |
EP2543678A1 (fr) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticorps pour la prévention et le traitement de la thrombose |
ES2656505T3 (es) | 2011-09-16 | 2018-02-27 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Exotoxina A de Pseudomonas con epítopos de linfocitos B menos inmunogénicos |
US9676847B2 (en) | 2012-06-25 | 2017-06-13 | Orega Biotech | IL-17 antagonist antibodies |
US9695247B2 (en) | 2012-09-03 | 2017-07-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies directed against ICOS for treating graft-versus-host disease |
AU2013204200B2 (en) | 2012-10-11 | 2016-10-20 | Brandeis University | Treatment of amyotrophic lateral sclerosis |
CN109180815B (zh) | 2012-11-20 | 2022-06-21 | 赛诺菲 | 抗ceacam5抗体及其用途 |
EA201690004A1 (ru) | 2012-12-27 | 2016-07-29 | Санофи | Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение |
US10005839B2 (en) | 2013-05-17 | 2018-06-26 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antagonist of the BTLA/HVEM interaction for use in therapy |
WO2014205187A1 (fr) | 2013-06-20 | 2014-12-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Sous-unité b de toxine cytolétale distendante conjuguée ou fusionnée à un facteur létal de toxine de bacillus anthracis |
CA2926215A1 (fr) | 2013-10-06 | 2015-04-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Exotoxine a de pseudomonas modifiee |
MX2016005854A (es) | 2013-11-07 | 2017-07-28 | Inserm (Institut Nat De La Santé Et De La Rech Médicale) | Anticuerpo anti-her3 alosterico de la neuregulina. |
ES2924393T3 (es) | 2014-04-16 | 2022-10-06 | Inst Nat Sante Rech Med | Anticuerpos para la prevención o el tratamiento de episodios hemorrágicos |
FR3021970B1 (fr) | 2014-06-06 | 2018-01-26 | Universite Sciences Technologies Lille | Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs |
MA40801A1 (fr) | 2015-01-23 | 2018-07-31 | Sanofi Sa | Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123 |
WO2016128349A1 (fr) | 2015-02-09 | 2016-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticorps anti-glycoprotéine (gp) de virus ebola et leurs utilisations pour le traitement et le diagnostic d'une infection provoquée par le virus ebola |
WO2016162368A1 (fr) | 2015-04-07 | 2016-10-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Imagerie non invasive de l'expression de pd-l1 d'une tumeur |
EP3319990A1 (fr) | 2015-07-07 | 2018-05-16 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Anticorps présentant une spécificité à la myosine 18a et leurs utilisations |
WO2017060397A1 (fr) | 2015-10-09 | 2017-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés de prédiction du temps de survie de sujets souffrant de métastases d'un mélanome |
CA3013333A1 (fr) | 2016-02-26 | 2017-08-31 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anticorps presentant une specificite pour btla et leurs utilisations |
US11234445B2 (en) * | 2016-03-18 | 2022-02-01 | Genclis | Molecular origin of allergy |
WO2017214186A1 (fr) | 2016-06-09 | 2017-12-14 | University Of Leicester | Anticorps monoclonaux, compositions et méthodes de détection de la protéine de type mucine (mlp) en tant que biomarqueur du cancer de l'ovaire et du pancréas |
CN109661406A (zh) | 2016-07-29 | 2019-04-19 | 国家医疗保健研究所 | 靶向肿瘤相关巨噬细胞的抗体及其用途 |
TW202300515A (zh) | 2016-10-20 | 2023-01-01 | 法商賽諾菲公司 | 抗chikv抗體及其用途 |
KR101885007B1 (ko) * | 2016-12-22 | 2018-08-31 | 가천대학교 산학협력단 | 인지기능장애의 진단 방법 및 키트 |
US11274160B2 (en) | 2017-03-02 | 2022-03-15 | INSERM (Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to Nectin-4 and uses thereof |
CN110382544B (zh) | 2017-03-16 | 2023-12-22 | 先天制药公司 | 用于治疗癌症的组合物和方法 |
US11174322B2 (en) | 2017-07-24 | 2021-11-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies and peptides to treat HCMV related diseases |
JP7226833B2 (ja) | 2017-09-21 | 2023-02-21 | イムチェック セラピューティクス エスエーエス | Btn2に特異性を有する抗体及びその使用 |
MA52870A (fr) * | 2018-06-13 | 2021-04-21 | Acraf | Peptides ayant une activité inhibitrice sur le récepteur muscarinique m3 |
KR20210023983A (ko) | 2018-06-18 | 2021-03-04 | 이나뜨 파르마 | 암을 치료하기 위한 조성물 및 방법 |
EP3826669A2 (fr) * | 2018-07-26 | 2021-06-02 | Frame Pharmaceuticals B.V. | Vaccins standard contre le cancer |
WO2020053122A1 (fr) | 2018-09-10 | 2020-03-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinaison d'anticorps her2/neu avec de l'hème pour le traitement du cancer |
CA3134122A1 (fr) | 2019-03-20 | 2020-09-24 | Imcheck Therapeutics Sas | Anticorps ayant une specificite pour btn2 et leurs utilisations |
WO2020193520A1 (fr) | 2019-03-25 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Traitement de troubles de tauopathie par ciblage de nouvelles espèces tau |
EP4007775A1 (fr) | 2019-08-02 | 2022-06-08 | Orega Biotech | Nouveaux anticorps il-17b |
CN114450304B (zh) | 2019-09-27 | 2023-12-12 | 国家医疗保健研究所 | 抗苗勒管抑制物质抗体及其用途 |
WO2021058729A1 (fr) | 2019-09-27 | 2021-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticorps dirigés contre le récepteur de type i d'une substance inhibitrice anti-mullérienne et leurs utilisations |
WO2021116119A1 (fr) | 2019-12-09 | 2021-06-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticorps présentant une spécificité pour her4 et leurs utilisations |
WO2021175954A1 (fr) | 2020-03-04 | 2021-09-10 | Imcheck Therapeutics Sas | Anticorps ayant une spécificité pour btnl8 et leurs utilisations |
BR112022020477A2 (pt) | 2020-04-24 | 2022-11-29 | Sanofi Sa | Combinações antitumor contendo conjugados de anticorpo anti-ceacam5 e cetuximabe |
CN115484989A (zh) | 2020-04-24 | 2022-12-16 | 赛诺菲 | 含有抗ceacam5抗体缀合物、曲氟尿苷和三氟尿嘧啶的抗肿瘤组合 |
IL297311A (en) | 2020-04-24 | 2022-12-01 | Sanofi Sa | Antitumor combinations containing conjugates of antibodies to ceacam5 and folfox |
KR20230005257A (ko) | 2020-04-24 | 2023-01-09 | 사노피 | 항-ceacam5 항체 접합체 및 folfiri를 함유하는 항종양 병용물 |
WO2021228956A1 (fr) | 2020-05-12 | 2021-11-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nouveau procédé de traitement de lymphomes cutanés à lymphocytes t et de lymphomes dérivés de tfh |
CN116113439A (zh) | 2020-09-04 | 2023-05-12 | 默克专利股份公司 | 抗ceacam5抗体和缀合物及其用途 |
CA3208974A1 (fr) | 2021-01-20 | 2022-07-28 | Bioentre Llc | Proteines de liaison a ctla4 et methodes de traitement du cancer |
CA3226537A1 (fr) | 2021-07-29 | 2023-02-02 | Ana HENNINO | Proteine anti-.beta.ig-h3 humaine humanisee et ses utilisations |
CA3237142A1 (fr) | 2021-11-05 | 2023-05-11 | Sanofi | Combinaisons antitumorales contenant des conjugues anticorps-medicament anti-ceacam5 et des anticorps anti-vegfr-2 |
WO2023150181A1 (fr) | 2022-02-01 | 2023-08-10 | President And Fellows Of Harvard College | Méthodes et compositions pour le traitement du cancer |
WO2023170240A1 (fr) | 2022-03-09 | 2023-09-14 | Merck Patent Gmbh | Anticorps anti-ceacam5 et conjugués et leurs utilisations |
WO2023172968A1 (fr) | 2022-03-09 | 2023-09-14 | Merck Patent Gmbh | Anticorps anti-gd2, immunoconjugués et leurs utilisations thérapeutiques |
WO2023240287A1 (fr) | 2022-06-10 | 2023-12-14 | Bioentre Llc | Combinaisons de protéines de liaison à ctla4 et procédés de traitement du cancer |
WO2024052503A1 (fr) | 2022-09-08 | 2024-03-14 | Institut National de la Santé et de la Recherche Médicale | Anticorps présentant une spécificité pour ltbp2 et leurs utilisations |
WO2024056668A1 (fr) | 2022-09-12 | 2024-03-21 | Institut National de la Santé et de la Recherche Médicale | Nouveaux anticorps anti-itgb8 et leurs utilisations |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8718779D0 (en) * | 1987-08-07 | 1987-09-16 | Grosveld F G | Dna sequence & expression vector |
US5015570A (en) * | 1988-05-13 | 1991-05-14 | Molecular Therapeutics, Inc. | Molecular diagnosis of Alzheimer Disease |
EP0451700A1 (fr) * | 1990-04-10 | 1991-10-16 | Miles Inc. | Minigènes APP recombinants pour l'expression dans des souris transgéniques comme modèles de la maladie d'Alzheimer |
US5455169A (en) * | 1992-06-04 | 1995-10-03 | Alzheimer's Institute Of America, Inc. | Nucleic acids for diagnosing and modeling Alzheimer's disease |
AU4769893A (en) * | 1992-07-17 | 1994-02-14 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of animal diseases |
US5854392A (en) * | 1992-08-31 | 1998-12-29 | Bristol-Myers Squibb Company | β APP-C100 receptor |
US5449604A (en) * | 1992-10-21 | 1995-09-12 | University Of Washington | Chromosome 14 and familial Alzheimers disease genetic markers and assays |
GB9410922D0 (en) * | 1994-06-01 | 1994-07-20 | Townsend Alain R M | Vaccines |
WO1997012992A2 (fr) * | 1995-10-02 | 1997-04-10 | Royal Netherlands Academy Of Arts And Sciences | Procede et reactifs de diagnostic |
-
1998
- 1998-04-02 WO PCT/IB1998/000705 patent/WO1998045322A2/fr not_active Application Discontinuation
- 1998-04-02 CA CA002287084A patent/CA2287084A1/fr not_active Abandoned
- 1998-04-02 JP JP54254598A patent/JP2001522241A/ja active Pending
- 1998-04-02 EP EP98917502A patent/EP0971952A2/fr not_active Withdrawn
- 1998-04-02 AU AU70715/98A patent/AU7071598A/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005026353A1 (fr) * | 2003-09-16 | 2005-03-24 | Sumitomo Chemical Company, Limited | Procede pour evaluer le degre de cancerisation |
US8980559B2 (en) | 2003-09-16 | 2015-03-17 | Sumitomo Chemical Company, Limited | Method for assessing cancerous state |
Also Published As
Publication number | Publication date |
---|---|
EP0971952A2 (fr) | 2000-01-19 |
CA2287084A1 (fr) | 1998-10-15 |
WO1998045322A3 (fr) | 1999-04-15 |
WO1998045322A2 (fr) | 1998-10-15 |
AU7071598A (en) | 1998-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001522241A (ja) | 診断方法および試薬 | |
JP3220752B2 (ja) | Mts−1遺伝子により転移性癌の診断 | |
KR20200044793A (ko) | Aav의 전달을 위한 조성물 및 방법 | |
US7041291B2 (en) | Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor | |
JP5830213B2 (ja) | Mecp2e1遺伝子 | |
JP2802634B2 (ja) | トランスカリオチック移植 | |
JPH06508030A (ja) | ヒトすい島グルタミン酸デカルボキシラーゼ自己抗原のクローニング及び発現 | |
JP2002512521A (ja) | 32個のヒト分泌タンパク質 | |
US20130330740A1 (en) | Novel therapeutic and diagnostic products and methods | |
US5552537A (en) | IgE isoforms and methods of use | |
CN110430899B (zh) | 光感受灵敏度的抑制或减弱剂 | |
JP2002514925A (ja) | 19個のヒト分泌タンパク質 | |
JPH10165187A (ja) | 新規唾液結合蛋白質 | |
JP2000511410A (ja) | ナンセンス介在rna崩壊の哺乳動物の調節因子 | |
JPH05501951A (ja) | 組換えヒト甲状腺ペルオキシダーゼ | |
WO2006093034A1 (fr) | Gene lie aux troubles mentaux et utilisation de celui-ci | |
JP2008504270A (ja) | 嚢胞性疾患を処置するための方法および組成物 | |
US10577657B2 (en) | MECP2E1 gene | |
Liu et al. | Localization of glutamic acid decarboxylase in the kidneys of nonobese diabetic mice | |
JPH10506529A (ja) | ヒト・ガラクトキナーゼ遺伝子 | |
WO2004055211A2 (fr) | Compositions et methodes pour la detection et le traitement de pathologies neurodegénératives | |
Keeton | Analyses of the genetic diversity of the calmodulin-sensitive plasma membrane calcium ATPases | |
JPWO2003083110A1 (ja) | 新規ガラクトース転移酵素、そのペプチド及びこれをコードする核酸 | |
CA2244744A1 (fr) | Compositions de genes lyst1 et lyst2 et leurs procedes d'utilisation | |
FR2824332A1 (fr) | Acide nucleique codant le polypeptide cgl1 et application de cet acide nucleique et du polypeptide cgl1 au diagnostic et en therapeutique |